Sabatolimab Biosimilar - Research Grade

Human

Tim-3

>1mg/ml

Human IgG4 S228P Kappa

Anti-Mouse Tim-3 (RMT3-23) In Vivo Antibody - Low Endotoxin (ICH1133), Anti-Mouse TIM-3 (B8.2C12) In Vivo Antibody - Low Endotoxin (ICH1250), Cobolimab Biosimilar - Research Grade (ICH5442), Surzebiclimab Biosimilar - Research Grade (ICH5888), Verzistobart Biosimilar - Research Grade (ICH5976)

https://www.imgt.org/mAb-DB/

ICH3002

Q8TDQ0

84868

RRID:AB_2921621

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-TIM-3 antibody sabatolimab, supplied strictly for research use only. It is built around the human TIM-3 (HAVCR2) target and formatted as a human IgG4 with the S228P hinge-stabilizing mutation and a kappa light chain, matching the immunomodulatory framework of the originator. It is not the clinical drug and is not intended for human or veterinary use. The analog is useful as a defined reagent for in-vitro and preclinical work: as a positive control or reference binder in TIM-3 binding and blockade assays, for benchmarking novel anti-TIM-3 candidates, for epitope-competition and receptor-ligand interference studies, and as a tool in ADCC/ADC-development and screening workflows. Because it is offered at research grade with low endotoxin (typically less than 1 EU/mg, with ultra-low-endotoxin options below 0.5 EU/mg) and in bulk milligram-to-gram quantities, it suits assay standardization, formulation and analytical method development, and larger screening campaigns where consistent, well-characterized material is required. TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), encoded by HAVCR2 (UniProt Q8TDQ0), is a type I transmembrane receptor and immune checkpoint expressed on exhausted and dysfunctional T cells, Tregs, NK cells, and myeloid cells including dendritic cells; in myeloid malignancies it is notably present on leukemic stem cells and blasts. Its extracellular IgV domain engages multiple ligands, including galectin-9, phosphatidylserine, HMGB1, and CEACAM1. Ligand engagement generally delivers inhibitory or exhaustion-associated signals that dampen effector T-cell and NK-cell responses, and TIM-3 is frequently co-expressed with PD-1 on severely exhausted T cells in tumors and chronic infection. Because it marks and modulates dysfunctional immune populations, TIM-3 is a prominent checkpoint target for antibody-mediated blockade aimed at restoring anti-tumor immunity, both alone and in combination with PD-1/PD-L1 blockade.

HAVcr-2, T-cell immunoglobulin and mucin domain-containing protein 3, TIMD-3, T-cell immunoglobulin mucin receptor 3, T-cell membrane protein 3, Hepatitis A virus cellular receptor 2

Detects human Tim-3. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sabatolimab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0043

Sabatolimab (anti-Tim-3) Biosimilar

Q: Is the Sabatolimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Sabatolimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Sabatolimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Sabatolimab that binds human Tim-3.